Table 2. Impact of turmeric or curcumin extracts on outcomes.11-14.
| Turmeric/Curcumin | Placebo | Active vs. placebo change from baseline | |||
|---|---|---|---|---|---|
| Panahi 2018 (n=36) | |||||
| ALT | Baseline: 40.7 (SD 15.0) | -- | -- | ||
| Final: 22.0 (SD 7.2)^ | -- | -- | |||
| AST | Baseline: 35.4 (SD 11.9) | -- | -- | ||
| Final: 22.6 (SD 7.2)^ | -- | -- | |||
| NAFLD | Before Grade 0: 0.0% |
After^
11.1% |
-- | -- | -- |
| Grade 1: 50.0% | 36.1% | -- | -- | ||
| Grade 2: 38.9% | 52.8% | -- | -- | ||
| Grade 3: 9.1% | 0.0% | -- | -- | ||
| Panahi 2017 (n=87) | |||||
| ALT | Baseline: 35.46 (SD 22.97) | Baseline: 36.81 (SD 24.32) | -10.61 (SD 15.49) vs. +4.51 (SD 7.40)# | ||
| Final: 24.85 (SD 12.84)^ | Final: 41.33 (SD 23.97)* | ||||
| AST | Baseline: 27.63 (SD 11.35) | Baseline: 27.44 (SD 10.01) | -6.95 (SD 7.47) vs. +3.79 (SD 6.43)# | ||
| Final: 20.68 (SD 6.65)^ | Final: 31.23 (SD 12.80)* | ||||
| NAFLD Severity | Before Grade 0: 0.0% |
After^
34.1% |
Before Grade 0: 0.0% |
After *
2.3% |
NAFLD severity improved in 75% vs. 4.7%#
NAFLD severity worsened in 4.5% vs. 25.6%# |
| Grade 1: 38.6% | 47.7% | Grade 1: 39.5% | 23.3% | ||
| Grade 2: 52.3% | 13.6% | Grade 2: 44.2% | 48.8% | ||
| Grade 3: 9.1% | 4.5% | Grade 3: 16.3% | 25.6% | ||
| Rahmani 2016 (n=77) | |||||
| ALT | Baseline: 39.07 (SD 19.79) | Baseline: 30.35 (SD 13.97) | -2.99 (SD 47.38) vs. -1.62 (SD 12.30)# | ||
| Final: 36.08 (SD 46.58)^ | Final: 28.72 (SD 10.93) | ||||
| AST | Baseline: 28.88 (SD 10.60) | Baseline: 32.05 (SD 17.64) | -5.04 (SD 6.49) vs. +2.02 (SD 11.79)# | ||
| Final: 23.84 (SD 7.83)^ | Final: 34.07 (SD 18.73) | ||||
| NAFLD Severity | Before Grade 0: 0.0% |
After^
15.8% |
Before Grade 0: 0.0% |
After 0.0% |
NAFLD severity improved in 78.9% vs. 27.5%#
NAFLD severity worsened in 0.0% vs. 17.5%# |
| Grade 1: 25.6% | 71.1% | Grade 1: 32.5% | 35.0% | ||
| Grade 2: 48.7% | 13.2% | Grade 2: 55.0% | 60.0% | ||
| Grade 3: 25.6% | 0.0% | Grade 3: 12.5% | 5.0% | ||
| Navekar 2017 (n=42) | |||||
| ALT | Baseline: 23.07 (Range 9-112) | Baseline: 23.67 (Range: 10-125) | Mean difference = -2.25 (95% CI: -8.96 to 4.45) | ||
| Final: 19.87 (Range 10-51) | Final: 22.85 (Range 10-60) | ||||
| AST | Baseline: 24.00 (SD 11.59) | Baseline: 24.33 (SD 13.69) | Mean difference = +0.49 (95% CI: -2.98 to 3.97) | ||
| Final: 24.14 (SD 8.90) | Final: 24.04 (SD 5.40) | ||||
| NAFLD Severity | Before Grade 0: 0.0% |
After 0.0% |
Before Grade 0: 0.0% |
After 0.0% |
No differences noted between groups |
| Grade 1: 57.1% | 66.7% | Grade 1: 47.6% | 66.7% | ||
| Grade 2: 42.9% | 33.3% | Grade 2: 52.4% | 33.3% | ||
| Grade 3: 0.0% | 0.0% | Grade 3: 0.0% | 0.0% | ||
^
Denotes significant intragroup DECREASES from baseline.
*
Denotes significant intragroup INCREASES from baseline.
#
denotes significant intergroup differences between groups. -- = No Control Group/Not Applicable, NG = Not Given.